CBD could lessen lung harm brought about by COVID-19 Kumar Jeetendra | October 19, 2020 One way CBD appears to reduce the”cytokine storm” that damages the lungs and kills many individuals with COVID-19 is by enabling an increase in levels of a natural peptide called apelin, which is proven to reduce inflammation and whose levels are dramatically reduced in the face of this storm. Dental College of Georgia and Medical …
Engineered counter acting agent may forestall Covid from contaminating human cells Kumar Jeetendra | November 4, 2020 By screening hundreds of artificial antibodies, researchers at Karolinska Institutet in Sweden and EMBL Hamburg in Germany have identified an antibody that may prevent the new coronavirus from infecting human cells. The analysis, which is printed in the journal Nature Communications, also reveals how electrons can be quickly generated in the event of future pandemics. …
Researchers discover proof that SARS-CoV-2 infects cells in the mouth Kumar Jeetendra | March 25, 2021 An international group of scientists has discovered evidence that SARS-CoV-2, the virus that causes COVID-19, infects cells in the mouth. While it’s well known that the upper airways and lungs are primary sites of SARS-CoV-2 disease, there are clues the virus can infect cells in different parts of the body, like the digestive system, blood …
Scientists use genetics to recognize likely drugs for early administration of COVID-19 Kumar Jeetendra | April 12, 2021 A new study using human genetics indicates researchers should prioritize clinical trials of drugs that target two proteins to manage COVID-19 in its early stages. The findings appeared online in the journal Nature Medicine at March 2021. The purpose is to identify present drugs, either FDA-approved or in clinical development for other conditions, that can …
Novel antibody candidate shows powerful binding to different SARS-CoV-2 variant mutations Kumar Jeetendra | September 25, 2021 Twist Bioscience Corporation today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19. The Coronavirus Immunotherapy Consortium (CoVIC) is an academic-industry-non-profit …
Nano-bubbles containing ACE2 protein can hinder contamination from wide strains of SARS-CoV-2 Kumar Jeetendra | January 21, 2022 Northwestern Medicine and The University of Texas MD Anderson Cancer Center discovered that natural nano-bubbles containing ACE2 protein (evACE2) were found in the blood of COVID-19 victims. They also discovered that these particles could block infection by broad strains of SARS/CoV-2 virus. Scientists said that the evACE2 acts in the body as a decoy and …
